Skip to main content
Premium Trial:

Request an Annual Quote

If It's Worth Doing, It's Worth Doing Right (FDA, That Means You)

A Wall Street Journal article reports on Harvard professor Daniel Carpenter, who is defending research indicating that the US FDA made "overly hasty approval decisions on medicines," now that FDA has criticized the research as flawed. Evidently, the original study did have mistakes -- but Carpenter says that coincides with errors in the FDA's own records. He says that "after he made necessary corrections, his original finding still held: Drugs that the FDA has approved soon before a regulatory deadline have been more likely to develop severe safety problems later on," according to the article.

 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.